Alexion Pharmaceuticals (ALXN) : Orbimed Advisors reduced its stake in Alexion Pharmaceuticals by 11.52% during the most recent quarter end. The investment management company now holds a total of 2,638,011 shares of Alexion Pharmaceuticals which is valued at $313,633,128 after selling 343,400 shares in Alexion Pharmaceuticals , the firm said in a disclosure report filed with the SEC on Nov 14, 2016.Alexion Pharmaceuticals makes up approximately 3.82% of Orbimed Advisors’s portfolio.
Other Hedge Funds, Including , Millennium Management boosted its stake in ALXN in the latest quarter, The investment management firm added 85,454 additional shares and now holds a total of 1,004,398 shares of Alexion Pharmaceuticals which is valued at $119,412,878. Alexion Pharmaceuticals makes up approx 0.23% of Millennium Management’s portfolio.Alliancebernstein boosted its stake in ALXN in the latest quarter, The investment management firm added 424,660 additional shares and now holds a total of 2,894,420 shares of Alexion Pharmaceuticals which is valued at $367,244,010. Alexion Pharmaceuticals makes up approx 0.31% of Alliancebernstein’s portfolio.Granite Point Capital Management reduced its stake in ALXN by selling 5,500 shares or 55.0% in the most recent quarter. The Hedge Fund company now holds 4,500 shares of ALXN which is valued at $572,220. Alexion Pharmaceuticals makes up approx 0.51% of Granite Point Capital Management’s portfolio.Blackrock Group Ltd reduced its stake in ALXN by selling 3,823 shares or 0.19% in the most recent quarter. The Hedge Fund company now holds 2,031,472 shares of ALXN which is valued at $243,878,214. Alexion Pharmaceuticals makes up approx 0.13% of Blackrock Group Ltd’s portfolio.California Public Employees Retirement System reduced its stake in ALXN by selling 31,800 shares or 6.11% in the most recent quarter. The Hedge Fund company now holds 488,591 shares of ALXN which is valued at $59,417,552. Alexion Pharmaceuticals makes up approx 0.10% of California Public Employees Retirement System’s portfolio.
Alexion Pharmaceuticals closed down -3.12 points or -2.54% at $119.85 with 15,23,614 shares getting traded on Monday. Post opening the session at $122.49, the shares hit an intraday low of $119.7 and an intraday high of $124.04 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Alexion Pharmaceuticals reported $1.23 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $1.17. The company had revenue of $799.10 million for the quarter, compared to analysts expectations of $786.61 million. The company’s revenue was up 19.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.16 EPS.
Many Wall Street Analysts have commented on Alexion Pharmaceuticals. Deutsche Bank Initiated Alexion Pharmaceuticals on Nov 3, 2016 to “Buy”, Price Target of the shares are set at $164.Alexion Pharmaceuticals was Upgraded by Goldman to ” Buy” on Oct 28, 2016. Company shares were Reiterated by Wedbush on Oct 28, 2016 to “Neutral”, Firm has raised the Price Target to $ 135 from a previous price target of $132 .
Alexion Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23 2015 the Company had eight product candidates in clinical trials for 11 indications. The Company’s product pipeline includes complement inhibitor portfolio metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris ALXN1007 ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq Kanuma ALXN1101 and SBC-103. The Company’s preclinical candidates include mRNA Therapies SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) two life-threatening ultra-rare disorders.